This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Merck (MRK) Slipped Today

NEW YORK (TheStreet) -- Merck (MRK - Get Report) slipped 2.6% to $45.35 in Monday trading after posting lower-than-expected third-quarter figures. Though earnings of 92 cents beat estimates by 4 cents, revenue of $11 billion missed expectations by $120 million according to analysts surveyed by Yahoo! Finance.

Sales of Merck's most profitable product, its diabetes treatment Januvia, dropped 5% to $927 million, while total pharmaceutical revenues was down 2% year on year to $9.48 billion.

"In order for us to grow next year, what we have to do is see a change in that volume," said President of Global Human Health Adam Schechter on a conference call, referring to Januvia sales. "If that volume continues to decline, obviously it's going to be a problem for us to grow."

Schechter credits waning sales to decreased market share and an increase in new competitors in Januvia's drug class. 

Must Read: Himax (HIMX) Jumps on Google Glass Production Rumors

For full year 2013, the global health care company anticipates earnings between $3.48 and $3.52, higher than analyst expectations of $3.47. However, forecasts indicate revenues will drop between 5 and 6%.

TheStreet Ratings team rates Merck & Co as a Buy with a ratings score of B+. The team has this to say about their recommendation:

"We rate Merck & Co (MRK) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $54.85 -1.60%
AAPL $93.72 -1.20%
FB $117.63 0.77%
GOOG $693.39 0.34%
TSLA $240.71 -2.80%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,066.17 -9.64 -0.46%
NASDAQ 4,776.3210 -28.97 -0.60%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs